Elonva
·
- Prescription status not stated
- Urinary and reproductive system, hormones
- Active substance
- Corifollitropin alfa
- Made by
- Organon N.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Organon N.V. |
|---|---|
| Active substance | Corifollitropin alfa |
| Used in | Urinary and reproductive system, hormones |
| Classification | G03GA09 · Urinary and reproductive system, hormones |
| Authorised on | 2010-01-25 |
| Last updated by the regulator | 2025-10-30 |
| EMA product number | EMEA/H/C/001106 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).